The 340B program has always been a moving target. Legislation, manufacturer challenges, and HRSA guidance changes keep the landscape shifting. Here is what safety net providers should be watching over the next 12 to 24 months.
Legislative Activity
Multiple bills affecting 340B have been introduced at the federal level. Some aim to expand program eligibility and strengthen enforcement against manufacturers who restrict contract pharmacy access. Others propose new transparency requirements or program limitations.
At the state level, several states have passed or are considering laws that affect 340B contract pharmacy arrangements, manufacturer restrictions, and program oversight. Staying on top of state-level developments is just as important as tracking federal legislation.
Manufacturer Restrictions
The manufacturer restriction landscape continues to evolve. Some manufacturers have expanded restrictions. Others have modified their approaches in response to HRSA enforcement actions. Court cases challenging manufacturer authority to impose restrictions are working through the federal courts.
The outcomes of these cases could significantly reshape the contract pharmacy landscape. Safety net providers should build program structures that are flexible enough to adapt to whatever direction the courts take.
HRSA Guidance and Enforcement
HRSA has increased its audit activity and enforcement posture in recent years. Expect that trend to continue. The agency has also issued updated guidance on patient eligibility, contract pharmacy oversight, and compliance documentation.
Providers who stay current with HRSA guidance and proactively align their programs will be better positioned than those who wait for an audit to identify issues.
What to Do Now
You cannot predict every change. But you can build a program that is resilient to change. That means strong compliance foundations, diversified pharmacy networks, multiple revenue streams, and partnerships with organizations that stay ahead of the regulatory curve.
The providers who invest in program infrastructure today will be the ones who thrive regardless of what the next 24 months bring.
Ready to Take the Next Step?
MedMatrix stays ahead of 340B regulatory changes so our partners do not have to. Contact us at info@medmatrix-rx.com to get started.
